Non-small-cell lung cancer

Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Rafael Rosell(Instituto Oncológico Dr. Rosell), Antônio Rossi(Azienda Ospedaliera S.Giuseppe Moscati), David P. Carbone(The Ohio State University), Tony Mok(Chinese University of Hong Kong), Juliana Guarize(European Institute of Oncology), Lorenzo Spaggiari(European Institute of Oncology), Niki Karachaliou(Institut Català d'Oncologia), Francesco Petrella(European Institute of Oncology)
Nature Reviews Disease Primers
May 21, 2015
10.1038/nrdp.2015.9
Cited by 1,090

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k